Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling by Spender, Lindsay C. & Inman, Gareth J.
© 2014 Spender and Inman. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Cancer Management and Research 2014:6 27–38
Cancer Management and Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
27
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CMAR.S37745
Developments in Burkitt’s lymphoma: novel 
cooperations in oncogenic MYC signaling
Lindsay C Spender
Gareth J inman
Division of Cancer Research, Medical 
Research institute, Jacqui wood 
Cancer Centre, University of Dundee, 
Ninewells Hospital and Medical 
School, Dundee, UK
Correspondence: Lindsay C Spender, 
Gareth J inman 
Division of Cancer Research, Medical 
Research institute, Jacqui wood Cancer 
Centre, University of Dundee, James 
Arrott Drive, Ninewells Hospital and 
Medical School, Dundee, DD1 9SY, UK 
Tel +44 013 823 833 66 
Fax +44 013 823 864 19 
email l.spender@dundee.ac.uk, 
g.j.inman@dundee.ac.uk
Abstract: Burkitt’s lymphoma (BL) is an aggressive disorder associated with extremely high 
rates of cell proliferation tempered by high levels of apoptosis. Despite the high levels of 
cell death, the net effect is one of rapid tumor growth. The tumor arises within the germinal 
centers of secondary lymphoid tissues and is identifiable by translocation of the c-MYC gene 
into the immunoglobulin gene loci, resulting in deregulation of the proto-oncogene. Many 
of the major players involved in determining the development of BL have been characterized 
in human BL cell lines or in mouse models of MYC-driven lymphomagenesis. Both systems 
have been useful so far in characterizing the role of tumor suppressor genes (for example, 
p53), prosurvival signaling pathways, and members of the B-cell lymphoma-2 family of apop-
tosis regulators in determining the fate of c-MYC overexpressing B-cells, and ultimately in 
regulating lymphoma development. Signaling through phosphoinositide (PI)3-kinase stands 
out as being critical for BL cell survival. Recurrent mutations in ID3 or TCF3 (E2A) that 
promote signaling through PI3-kinase have recently been identified in human BL samples, and 
new therapeutic strategies based on coordinately targeting both the prosurvival factor, B-cell 
lymphoma-X
L
, and the PI3-kinase/AKT/mammalian target of rapamycin (mTOR) signaling 
pathway to synergistically induced BL apoptosis have been proposed. Now, engineering both 
constitutive c-MYC expression and PI3-kinase activity, specifically in murine B-cells undergo-
ing the germinal center reaction, has revealed that there is synergistic cooperation between 
c-MYC and PI3-kinase during BL development. The resulting tumors phenocopy the human 
malignancy, and acquire tertiary mutations also present in human tumors. This model may, 
therefore, prove useful in further studies to identify functionally relevant mutational events 
necessary for BL pathogenesis. This review discusses these cooperating interactions, the pos-
sible influence of BL tumor-associated viruses, and highlights potential new opportunities 
for therapeutic intervention.
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Introduction
Molecular pathology of Burkitt’s lymphoma
Burkitt’s lymphoma (BL) was originally identified by Dr Denis Burkitt in 1958 as 
an aggressive tumor of the jaw found in a cohort of children living in malarial areas 
of Africa (endemic BL).1 Today, this lymphoma is subdivided into three different 
subclasses with some distinct pathological features evident in each subtype. The 
second subgroup, sporadic BL, accounts for a high proportion of western pediatric 
lymphoma cases. These commonly arise within the ileum, but progress to involve 
the bone marrow or blood where circulating lymphoma cells are evident. The third 
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subgroup is associated with immunodeficiency, either as 
a consequence of human immunodeficiency virus (HIV) 
infection, or as a result of immunosuppressive therapy 
following organ transplantation. BL accounts for approxi-
mately 30% of those lymphomas related to HIV infection. 
Concurrent infection with the γ-herpesvirus, Epstein–Barr 
virus (EBV) is found in the majority of endemic BL cases, 
but EBV-positive lymphoma cells are also detected, to 
a variable degree, in sporadic (approximately 15%) and 
immunodeficiency-associated cases (between 40% and 
50%) depending upon the demographic.2 The common 
features of all subtypes are that they arise from differen-
tiating B-cells within germinal center (GC) reactions and 
carry somatic hyper-mutations of the B-cell receptor (BCR) 
immunoglobulin (Ig) heavy chain variable region, indicative 
of this site of origin.  Histologically, the lymphomas have a 
characteristic “starry sky” appearance and are comprised 
of densely packed, CD10/CD20/IgM-positive cells with 
a highly proliferative Ki-67-positive fraction of greater 
than 95%. Unlike follicular lymphoma, BLs are typically 
negative for the antiapoptotic protein, B-cell lymphoma 
(BCL)-2, again indicative of the cell of origin. All three 
subtypes also have a common genetic abnormality that 
is critically required for tumorigenesis. Deregulation and 
overexpression of the proto-oncogene c-MYC in BL is a 
result of translocation of the c-MYC gene on chromosome 
83,4 to either the heavy, light, or kappa chain Ig loci (t[8;14], 
t[2;8], or t[8;22] translocation) with t(8;14) being the most 
frequently observed. How malaria and EBV infections 
contribute to BL pathogenesis is not entirely understood, 
but they presumably help to establish a cellular- or micro-
environment conducive for c-MYC translocation and 
survival of the c-MYC overexpressing B-cell, eventually 
leading to lymphoma development. Their involvement in 
BL pathogenesis may well involve establishing a state of 
chronic B-cell proliferation and activation (as reviewed in 
the case of malaria by Moormann et al).5 The extraordinary 
ability of EBV to drive B-cell proliferation (interestingly, 
also involving a similar increase in c-MYC expression) while 
simultaneously abrogating apoptosis has also been reviewed 
elsewhere.6 This review will discuss both the effects of onco-
genic c-MYC deregulation in BL cells, and the subsequent 
cooperating events required for BL tumorigenesis.
c-MYC
The proto-oncogene c-MYC is commonly deregulated in 
human cancers. It is a member of the helix–loop–helix leu-
cine zipper family of nuclear transcription factors (TCFs), 
regulating the expression of a whole host of genes (and micro 
ribonucleic acids [micro RNAs])7,8 involved in signal trans-
duction, cell cycle regulation, metabolism, apoptosis, cell 
adhesion, and protein biosynthesis. The carboxyl-terminus 
of the 430aa protein contains a helix–loop–helix deoxyri-
bonucleic acid (DNA)-binding domain. The dimerization 
domain mediates heterodimerization with MYC associated 
factor X (MAX), and this complex formation is required for 
the conversion of MYC into an active polypeptide capable 
of binding enhancer box (E-box) target DNA sequences 
(5’-CACGTG-3’).9,10 MYC/MAX activity may itself be 
inhibited by the competitive binding of MAX by MAD1.11
Regulation of c-MYC expression is complex, occurring 
both at the level of gene transcription from one of four poten-
tial transcriptional promoters, and also via posttranslational 
modifications affecting protein stability. Moreover, c-MYC 
promoters P1 and P2 lie in the noncoding exon 1 of the gene, 
upstream of the coding exons 2 and 3. The vast majority 
(80%–90%) of MYC in normal cells is transcribed from P2; 
however, a switch to P1 promoter usage is observed following 
gene translocation when transcription falls under the control 
of Ig enhancer elements.12 The normal c-MYC allele is silent 
in BL.13,14 The c-MYC protein itself is normally degraded 
very rapidly, having a half-life of only 20–30 minutes. MYC 
is usually difficult to detect by Western blot analysis in normal 
cells, however, high protein expression levels are observed 
(and tolerated) in BL cell lines which necessitates mutational 
events and crosstalk with other signaling pathways (which 
will be discussed).
Functionally, in normal cells, c-MYC has an important 
role in increasing the mass of a cell prior to its division – a 
process required to maintain the size of the two resulting 
daughter cells. Hypofunctioning MYC in drosophila, results 
in a small-body phenotype (minutes) caused by decreased 
cell size (as opposed to fewer cell numbers).15 This phe-
notype correlates with a reduction in the expression of 
ribosomal protein genes required for protein synthesis.16 
MYC expression also subsequently promotes the cell 
division through the upregulation of cyclin D, E2F, and 
the cyclin-dependent kinase (CDK)4,17 while repressing 
genes involved in cell cycle arrest (p27, p15, p21, p57, 
growth arrest and DNA damage [GADD]45, GADD34, 
and GADD153).
Deregulation of MYC in BL is undoubtedly a potent pro-
moter of lymphocyte proliferation; however, overexpression 
of this proto-oncogene also induces powerful antiprolifera-
tive, apoptotic stress responses (Figure 1), which ultimately 
must be overcome for lymphomagenesis.
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Functions of c-MYC in BL
The role of MYC in BL development, as well as the tumor 
suppressor pathways employed in an attempt to control 
lymphocyte proliferation, have been studied in depth 
using various experimental approaches. These include the 
analysis of both established BL cell lines and the engineered 
c-MYC-inducible cell line; P493-6, as well as the study of 
mouse models of MYC-driven lymphomas (Eµ-Myc and 
iMYCEµ).18
It is clear that continuous MYC activity is required for BL 
lymphomagenesis. Pharmacological inhibition of MYC/MAX 
heterodimer formation and MYC function in BL cell lines 
(using 10058-F4; Sigma-Aldrich, St Louis, MO, USA)19 has 
demonstrated conclusively that c-MYC is essential for BL cell 
proliferation20,21 and survival.22 Using alternative approaches, 
conditional MYC expression systems have also been analyzed 
both in vitro and in vivo. Conditional activation of MYC in 
the P493-6 cell line, which contains an estrogen- regulatable 
estrogen receptor–c-MYC fusion protein, demonstrated that 
in BL cells (as in normal cells), c-MYC regulates cell growth 
through an increase in metabolism and protein synthesis. 
Following serum starvation, cell growth and division become 
uncoupled since the starved cells increase in size, but are 
unable to progress through the cell cycle. Proliferation itself 
is, therefore, dependent on serum factors.23,24 Conditional 
Tet-off MYC expression in murine lymphoid cells has also 
demonstrated that loss of transgenic MYC expression follow-
ing treatment with doxycycline results in a G1 cell cycle arrest 
and apoptosis of the MYC-driven lymphoma cells.25 MYC, 
however, does not appear to play a significant role in driving 
cells through stages of B-cell development since lymphomas 
in Eµ-MYC or MYC insertion iMYCEµ mice arise at the pre-
B-cell or mature stages (a deviation from a faithful pheno-
copy of the GC-derived human disease). More mechanistic 
8q24 translocation
c-MYC deregulation PI3K signaling
AKTc-MYC 
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Lymphomagenesis
Survival
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p21
p53
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Figure 1 Pathways regulating proliferation, survival, and cell death in BL.
Notes: BL is associated with chromosomal translocations that deregulate expression of the proto-oncogene c-MYC. Specifically, c-MYC increases cell size and cell 
proliferation in part through transcriptional induction of numerous genes including cyclin D, cyclin-dependent kinases, and E2F, which release cells from the G1/S cell 
cycle checkpoint regulated by RB/e2F. The capacity to regulate a vast array of cellular genes and drive cell proliferation is tempered by the induction of oncogene-induced 
apoptosis and senescence mediated by the ARF/p53 tumor suppressor pathway and “intrinsic” apoptosis. intrinsic, or mitochondrial, apoptosis is regulated by pro-apoptotic 
BH3-only members of the BCL-2 family (for example, BiM and PUMA). These proteins activate the mitochondrial membrane proteins BAX and BAK to induce the release 
of cytochrome c from mitochondria into the cytoplasm and activation of the caspase cascade. At each point the effect of c-MYC can be regulated by cross-talk with other 
signaling pathways including the pro-proliferative, prosurvival Pi3K/AKT pathway. The net outcome of cell cycle arrest and apoptosis versus proliferation and survival of 
B-cells carrying translocated c-MYC determines disease progression and lymphomagenesis.
Abbreviations: Pi3K, phosphoinositide 3-kinase; CDK4, cyclin-dependent kinase 4; HDM2, human double minute 2 homolog; PUMA, p53-upregulated modulator of 
apoptosis; BL, Burkitt’s lymphoma; RB, retinoblastoma; BH3, Bcl-2 homology 3; BCL-2, B-cell lymphoma 2.
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studies have examined the transcriptome associated with 
BL and MYC overexpression, either using the conditional 
systems mentioned above,26–28 or by genome-wide chromatin 
immunoprecipitation analysis of MYC DNA-binding sites 
in BL cell lines.29,30 What is evident from these studies is 
that MYC deregulation establishes a generalized increase in 
metabolic activity, gene transcription, and protein synthesis in 
the afflicted cell, rather than selective upregulation of certain 
cancer-causing genes (Figure 1). Since many of the MYC 
target genes are TCFs themselves,29 waves of time-dependent 
transcription are established through direct and indirect target 
gene regulation.31 The critical question to ask in order for us 
to understand how lymphomas develop following c-MYC 
translocation is what cooperating genetic alterations and muta-
tions enable a cell to tolerate such extensive transcriptional 
deregulation and oncogene-induced stress?
Cooperating mutations
Determining which cooperating mutations can promote the 
survival of MYC-driven lymphoma may help in the identifica-
tion of more selective targeted therapies. Genomic analysis 
has revealed that BLs are genomically heterogeneous, with 
70 genes identified as being recurrently mutated (and as 
many as 17 mutated per lymphoma).32 Recent advances in 
our understanding of these mutations will be discussed in 
the following sections.
Mutations in MYC
Levels of c-MYC, even in proliferating normal cells, are 
usually relatively low. Since MYC has a short half-life,33 any 
change in the transcriptional/translational output of the gene 
would therefore be “sensed” rapidly by the cell – a sensible 
precaution for such a potent metabolic and transcriptional 
activator. BL cells, which are dependent on continuous 
MYC expression for survival, select for cooperating events, 
which have the effect of increasing the availability of the 
transforming protein. These may involve crosstalk with 
activated signaling pathways (such as phosphoinositide 
3-kinase [PI3K], discussed later) or mutations within MYC 
itself. The amino-terminus transactivation domain of c-MYC 
contains two conserved, functionally critical MYC family 
regions called box 1 and box 2.34 Mutations within box 2 
identified within the BL samples affect the transform-
ing ability of MYC and its ability to promote apoptosis.35 
Box 1 contains phosphorylation sites involved in the pro-
teolysis of c-MYC by the ubiquitin–proteasome pathway.36 
 Residues within this region are mutated in approximately 
20% of BLs, especially at the hotspot residues 39, 57, and 
58. The threonine 58 (Thr58) to alanine mutation results in 
 inefficient ubiquitination, a decrease in proteasomal degrada-
tion, and thus, an increase in protein stability (Figure 2).37–39 
Thr58 is a target of glycogen synthase kinase (GSK)3β 
phosphorylation, an event that is dependent on phosphoryla-
tion of Serine (Ser)62 and the proline residue at position 57. 
Therefore, any mutation of Proline (Pro)57 would also inhibit 
Thr58 modification.40 The observation that the Thr58 mutation 
of c-MYC and the inactivating mutations of the p53 tumor 
suppressor pathway are mutually exclusive in BL, however, 
also implies that the mutation of MYC has a function in the 
avoidance of oncogene-induced apoptotic responses.
Avoiding oncogene-induced stress 
responses
Various mechanisms for avoiding such responses have been 
identified in BL and are represented schematically in Figure 2. 
Analysis of the murine lymphoma model indicates that acute 
MYC expression while inducing cell proliferation also induces 
apoptosis, provided that two requirements are met – the first 
being the activation of the p53 tumor suppressor pathway.
To activate the p53 pathway, p53 is stabilized through MYC/
Forkhead box protein (FOXO) transcription of the CDKN2A 
locus encoding p14ARF (named p19ARF in mice),41 which inhibits 
degradation of p53 by mouse double minute (MDM)2 homolog. 
The resulting induction of apoptosis42 and senescence43 in 
premalignant Eµ-Myc B-cells is rate limiting for lymphoma 
development. As might be predicted, p53 is frequently a target 
for mutation in BL.44,45 Elevated levels of MDM4,46 MDM2 
(called human double minute 2 homolog in humans) or loss of 
p14ARF expression have also been detected in BL cells carrying 
wild type p53,47 which would also have the effect of inactivat-
ing p53 tumor suppressor function. The activity of p53 may 
be reactivated in cases of elevated MDM2/4 expression using 
inhibitors of MDM2 activity to induce apoptosis.48
The second requirement for oncogene-induced apoptosis is 
the induction of BIM. BIM is a pro-apoptotic Bcl-2 homology 
3 (BH3)-only member of the BCL-2 family, which acts via the 
mitochondrial membrane proteins Bcl-2 associated X protein 
(BAX) and Bcl-2 homologous antagonist/killer (BAK) to induce 
intrinsic mitochondrial apoptosis (Figure 2). The loss of a single 
allele of BIM in Eµ-MYC mice accelerates the development of 
lymphomas.49 This decision point50 where both p53 and the 
mitochondrial apoptotic machinery must be engaged for com-
mitment to apoptosis is presumably a safeguard to ensure cell 
destruction only occurs when absolutely necessary. Lymphoma 
development applies a selective pressure such that at least one 
of these pathways must be inactivated. The evidence suggests 
that a loss of function of one of the arms of the stress response 
precludes any need for mutational inactivation of the other.51
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If, for example, BAX is experimentally inactivated (BAX 
activity being required for the BIM-induced apoptosis), the 
selection of p53 mutations in MYC-driven lymphoma is cir-
cumvented since the intrinsic pathway is now  nonfunctional.52 
Similarly the MYC Thr58 mutation, as discussed above, is 
seen only in BL with an intact p53 pathway, and so it must 
provide a function that is not needed in the context of inac-
tive p53. Analysis of lethally irradiated mice reconstituted 
with stem cells transfected with wild type or mutant MYC 
showed that this mutation, in fact, disables the ability of 
MYC to induce transcription of BIM, subsequently negating 
the intrinsic apoptosis arm of the oncogene-induced stress 
response. Consequently, only cells carrying wild type MYC 
developed inactivating p53 mutations. In biopsies of EBV-
positive BLs, the BIM promoter may also be methylated at 
CpG dinucleotides, suggesting that epigenetic silencing of 
BIM could play an important role in tumorigenesis.53,54
Interestingly, p53-upregulated modulator of apoptosis 
(PUMA), a BH3 protein functionally akin to BIM, is also 
involved in the p53-induced apoptotic response.55 While this 
protein is not mutated in BL, it may be subject to decreased 
expression through promoter methylation – even in tumors 
carrying mutant p5356 – suggesting that there are p53-
independent regulators of PUMA active in BL. We recently 
showed that PUMA is a downstream effector of a transform-
ing growth factor (TGF)-β-induced apoptosis pathway active 
(ABT-737)22
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AKT
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Figure 2 Cooperating mutational events in MYC-driven lymphomagenesis and novel therapeutic opportunities.
Notes: Continuous MYC expression is required for BL cell survival, as demonstrated by the apoptotic effect of the MYC inhibitor 10058-F4 on BL cell lines. (inhibitors 
of various pathway components are indicated in red lettering throughout, and appropriate references citing potential therapeutic approaches are indicated.) As a defense 
against continuous, high-level MYC expression and lymphoma development, the induction of rate-limiting apoptosis is most efficient when both the p53 and the BIM-induced 
apoptosis pathways are activated simultaneously. BLs undergo mutational and epigenetic changes during tumorigenesis to inactivate either one of these tumor suppressor 
pathways. Mutational events include loss of the p53 activator p14ARF, mutation of p53, or an increase in expression of its upstream regulators MDM2 or MDM4, which target 
p53 for proteasomal degradation. The effect of MDM2 can be inhibited by nutlin in cells carrying wild type p53 resulting in p53 activation and apoptosis. induction of the 
pro-apoptotic BH3-only protein BiM by MYC can be lost selectively in BL cells carrying mutant MYC protein. For example, MYC proteins mutated at Thr58 lose the ability to 
induce transcription of BIM. Transcription of BIM, or the p53 and TGF-β pro-apoptotic target gene PUMA, may also be suppressed through methylation of their promoters. 
BH3-mimetic compounds (ABT-737) are functionally similar to BiM and PUMA and have been shown to induce apoptosis of BL cell lines. Recent evidence has implicated 
signaling via Pi3K/AKT/mTOR as being a critical cooperating oncogenic pathway in the development of BL. BL tumors display mutations in TCF3 (E2A), ID3, and the inhibitory 
phosphatase, PTEN, that function to increase “tonic” B-cell receptor signaling through Pi3K. Tonic BCR signaling is used to describe low-level antigen-independent signaling 
by the B-cell receptor. TCF3 is a transcription factor normally regulated by iD3. Mutations in iD3 relieve repression of TCF3, resulting in TCF3-mediated expression of heavy 
and light immunoglobulin chains components of the BCR and increased BCR signaling. Cyclin D3 mutations are also recurrent, and BL cells are dependent on cyclin D/CDK6 
activity for proliferation. The stability of MYC itself is regulated by proteolysis through the ubiquitin/proteasome pathway. Targeting MYC for degradation is dependent on 
GSK3β-mediated phosphorylation of Thr58. MYC may be stabilized in BL either through a Thr58–alanine mutational substitution, or through GSK3β inactivation by the 
cooperating Pi3K pathway. Selectively blocking of Pi3K, AKT, and/or mTOR signaling using various inhibitors (shown in red) correlates with induction of BL cell apoptosis. in 
addition, mTORC1/2 signaling through 4e-BP1 and eiF4e (not shown) is required for 5’ cap-dependent protein translation. Blocking 4eBP-1 activity using selective inhibitors 
(PP242 or BeZ235) decreases the expression of the prosurvival factor MCL-1 and MYC (short-lived proteins requiring continuous 5’ cap-dependent protein translation for 
maintenance of expression), or induces BMF as a cellular stress response.
Abbreviations: CDK6, cyclin-dependent kinase 6; TCF3, transcription factor 3; BCR, B-cell receptor; GSK3β, glycogen synthase kinase 3β; Thr58, threonine 58; PTeN, 
phosphatase and tensin homolog; MDM2, mouse double minute 2 homolog; MDM4, mouse double minute 4 homolog; Pi3K, phosphoinositide 3-kinase; PUMA, p53-
upregulated modulator of apoptosis; TGF, transforming growth factor; mTOR, mammalian target of rapamycin; MCL-1, induced myeloid leukemia cell differentiation protein; 
S6K, ribosomal protein S6 kinase; BL, Burkitt’s lymphoma; BH3, Bcl-2 homology 3.
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in both human BL cell lines and murine Eµ-MYC-derived 
lymphoma cells.57 TGF-β also negatively regulates the BL 
survival factor, BCL-X
L
.58 The selective pressure used to 
reduce PUMA expression in lymphomas, therefore, may arise 
from either the induction of p53, or through activation of the 
TGF-β tumor suppressor pathway (Figure 2).
So far, the studies mentioned describe the impact of 
genetic changes directly affecting two rate-limiting tumor 
suppressor pathways acting through p53 and intrinsic 
 apoptosis. There is, however, evidence to implicate muta-
tional changes in other signaling pathways that indirectly 
impact on these tumor suppressor pathways. For instance, 
further mutations have been identified in BL samples which 
upregulate signaling through PI3K. This signaling pathway 
has a critical role in cooperating with MYC during lym-
phomagenesis and promoting BL survival. The involvement 
of PI3K signaling in BL pathogenesis and opportunities for 
therapeutic intervention will be discussed.
The role of Pi3K: MYC is not the only 
one “AKT”ing up to cause BL
BL development has only recently, for the first time, been mod-
eled faithfully in mice by Sander et al,59 who investigated the 
effects of coordinately targeting both c-MYC and constitutively 
active PI3K. The idea that PI3K activity may be required for 
survival of BL cells harboring high levels of c-MYC expression 
was certainly not new, given that there have been numerous 
previous studies linking c-MYC-mediated transformations 
with the requirement for PI3K activity.60–64 The dependence of 
human BL cells on PI3K activity for proliferation and survival 
was also demonstrated by Curnock and Knox65 over a decade 
ago using PI3K inhibitors, and by others since.22,66 However, 
the new mouse model advances our understanding in that MYC 
and PI3K activity were targeted specifically to cells undergoing 
the GC reaction. Thus, the model more accurately recapitulates 
oncogenic processes occurring at the site of origin of BL, and 
these data unequivocally link PI3K signaling with MYC as 
cooperating factors in the development of BL. The lympho-
mas that formed in this model were a phenocopy of human 
tumors in terms of histology, cell surface marker expression, 
and ongoing somatic hypermutations of Ig-variable regions 
(indicative of GC B-cells). Importantly, the tumors exhibited 
gene and protein expression profiles similar to human BL, 
which distinguished them from those seen in diffuse large 
B-cell lymphoma (DLBCL). The tumors also developed ter-
tiary stabilizing mutations in cyclin D3, an important regulator 
of GC B-cell proliferation,67,68 and frequently detected in BL 
samples.69 In addition to this advance, however, there have 
been exciting new discoveries as to how PI3K might be acti-
vated in BL, and what downstream effectors could be targeted 
effectively in new therapeutic strategies.
Significantly, Schmitz et al70 have identified recurrent 
mutations within approximately 70% of BL that increase 
signaling through PI3K. RNA sequencing on sporadic BL 
and BL cell lines revealed monoallelic mutations within 
TCF3 (also called E2A), biallelic mutations within its highly 
expressed negative regulator Inhibitor of DNA binding-3 
(ID3), as well as infrequent (7%) mutations of the inhibitory 
phosphatase, PTEN (see Figure 2). In normal B-cells, E2A 
is involved in antigen-dependent B-cell responses and is 
expressed within the dark zone of GCs.71 It is itself a target for 
translocation events in B-cell acute lymphoblastic leukemia. 
The mutant transcription factor 3 (TCF3) proteins identified 
in BLs escape from the inhibitory effects of the ID proteins 
to upregulate expression of the heavy and light Ig chains of 
the BCR. The authors suggest a dependency of BL cells on 
“tonic” BCR signaling for survival of the tumor cells. Such 
so-called tonic BCR signaling is a state of low-level BCR 
activation required for the survival of resting mature B cells 
in vivo. It involves constitutive signaling via Syk, but does not 
require binding of the BCR to its cognate antigen (antigen-
independent signaling). Like those seen in the Sander et al59 
mouse model, mutations in BL samples were also identified 
within the TCF3 target gene cyclin D3. Furthermore, using 
the CDK4/6 inhibitor PD 0332991 the study demonstrated 
that the BL cells were dependent on cyclin D3/CDK6 activity 
(regardless of the mutational status of the cyclin D3 gene), 
and that the cyclin D3 mutations augmented cell cycle pro-
gression. Similar recurrent ID3 mutations were independently 
identified in BL (but notably not in diffuse large BCL also 
carrying MYC translocations);32,72 however, no global gene 
expression differences between cells carrying wild type or 
mutant ID3 were evident in this study.72
Interestingly, Love et al,32 in addition to identifying 
ID3 mutations in BL, also identified recurrent mutations in 
PI3KR1. The class 1 PI3Ks are comprised of a heterodimer 
made up of a catalytic subunit (p110α, p110β, or p110δ) 
and one of three regulatory subunits (p85α, p55α, and p50α, 
which are all derived from the same gene, PI3KR1). It is note-
worthy that the p55α regulatory subunit is induced following 
infection of primary B-cells with the BL-associated virus 
EBV, and is required for the survival and proliferation of lym-
phoblastoid cell lines.73 However, the functional significance 
of the mutations in PI3KR1, or the differential induction of 
regulatory subunits by EBV, have not been investigated in the 
context of lymphoma and warrant further study.
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As in other cancer types,74 signaling through PI3K may 
also be involved in stabilizing MYC through regulation of 
GSK3β activity.75 The MYC p-Thr58 modification, medi-
ated by GSK3β and required for MYC degradation, can be 
blocked via a PI3K-dependent inhibitory phosphorylation of 
GSK3β on Ser9. Potentially, constitutive PI3K activation in 
BL carrying wild type MYC would help promote its stability 
and may contribute to its tumorigenic effects. In addition, 
PI3K/AKT activation in the context of MYC-induced trans-
formation interferes with the oncogene-induced apoptotic 
response, again through an inhibitory modification, but this 
time, by phosphorylation of FOXO TCFs downstream of 
MYC. Although described in an artificial in vitro MycER 
system, inhibition of FOXO activity by AKT is required for 
MYC-induced transformation and proliferation,64 and it has 
been reported that PI3K/AKT and MYC together coopera-
tively repress PUMA and GADD45a expression by block-
ing their FOXO-dependent transcription (independently of 
PUMA induction by p53).76 If inhibition of FOXO-mediated 
transcription by PI3K/AKT signaling also occurs in MYC-
driven lymphomas, it could potentially contribute to some 
of the cooperation seen between MYC and PI3K. Indeed, 
using a dominant negative FOXO protein to inhibit FOXO 
transcription accelerates lymphomagenesis in Eµ-MYC mice 
by attenuating MYC-induced apoptosis.41 In this case, the 
authors attribute the effect to a loss of transcription of the 
p53 regulator p19ARF, which correlated with reduced p53 
and PUMA induction. In either event, posttranslational 
modifications of AKT substrates involved in oncogene-
induced apoptosis are likely, at least in part, to account 
for the cooperative effects of MYC and AKT seen during 
lymphomagenesis. The alternative potential prosurvival 
mechanisms of AKT, which could be involved in subverting 
MYC-induced apoptosis include phosphorylation of HDM2, 
which increases its ligase activity and results in enhanced 
degradation of p53,77 blocking caspase activity,78 and increas-
ing expression of prosurvival BCL-2 family members, such 
as induced myeloid leukemia cell differentiation protein 
MCL-1 (discussed in the following section).
The role of the AKT substrate mTOR  
and therapeutic opportunities
In a recent in vitro mechanistic study using selective pharma-
cological inhibitors to treat BL cell lines, we analyzed which 
effectors downstream of PI3K are critical for BL survival.22 
In agreement with previous work,66 apoptosis of BL cell 
lines is induced by the PI3K inhibitor (LY-294002) and also 
by the dual PI3K/mTOR inhibitor PI103. The AKT inhibitor 
(AKTi-VIII) also induces BL apoptosis as a single agent, 
confirming that PI3K signaling via AKT is important for BL 
survival. Data on Eµ-MYC mice treated with the allosteric 
AKT inhibitor MK-2206 have now also demonstrated that 
AKT activity is required for lymphoma progression in vivo.79 
However, further analysis using inhibitors of the downstream 
effectors of AKT activity have identified functions of mTOR 
in both BL survival and chemoresistance.
It should be noted that mTOR exists as two complexes: 
mTORC2 (acting upstream of AKT), and the AKT sub-
strate mTORC1, which regulates the AKT effectors p70 
S6-kinase/S6 ribosomal protein, and 4E-BP1/eIF4E. Using 
PP242, an active site adenosine triphosphate-competitive 
inhibitor of both mTORC1 and mTORC2, as well as low doses 
of rapamycin (an inhibitor of mTORC1), we were able to 
distinguish between the rapamycin-sensitive and rapamycin-
insensitive effects80–83 of mTORC1 signaling in order to 
dissect the critical pathway components. PP242 inhibited 
phosphorylation of both S6 ribosomal protein and 4E-BP1, 
whereas rapamycin only inhibited phosphorylation of the S6 
ribosomal protein. These studies revealed that the proapop-
totic effects of PI3K/AKT/mTOR inhibitors correlated with 
an inhibition of 4E-BP1/eIF4E function, suggesting that 
inhibition of cap-dependent protein translation mediates 
the apoptotic effect in BL cells. (It is worth noting here that 
higher doses of rapamycin can inhibit both S6K and 4E-BP1 
and, therefore, do not always discriminate between different 
mTOR functions in every study reported.) It is possible that 
activation of the S6-kinase by mTOR could additionally have 
a positive effect on MYC-mediated transcription through 
the phosphorylation and degradation of the MYC inhibitor, 
MAD1,84 but in terms of 4E-BP1 function, it is interesting to 
note that the activity of eIF4E has been previously reported 
to rescue cells from MYC-induced apoptosis.85 We found 
that inhibition of the PI3K/AKT/mTOR signaling pathway 
in BL cells decreased the expression of both c-MYC and 
MCL-1 (a prosurvival member of the BCL-2 family). Both 
proteins, which are short-lived, require continual protein 
synthesis for the maintenance of expression levels such that 
the inhibition of cap-dependent translation would rapidly 
affect their level of expression. In support of these findings, 
enhanced mTORC1 activity in mice (in the Eµ-MYC/TSC2+/– 
model) accelerates MYC-driven oncogenesis through lower 
levels of apoptosis and increased mTORC1-dependent 
MCL-1 expression.86 In addition, targeting mTORC1 with 
Everolimus (RAD001; Novartis AG, Basel, Switzerland), 
an inhibitor that is now being investigated in clinical trials, 
both protected Eµ-MYC mice from lymphoma development 
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and induced regression of preformed lymphoma.87 Further 
evidence to support the conclusion that 4E-BP1 activity is 
important for lymphoma survival has subsequently been 
reported using the pan PI3K/mTOR inhibitor BEZ235 in the 
Eµ-MYC murine model. In this case, apoptosis was reported 
to be dependent on upregulation of the BH3-only protein 
Bcl-2 modifying factor (BMF), which is induced in response 
to inhibition of 4E-BP1/eIF4E mediated 5’ cap-dependent 
protein translation.88,89 Furthermore Eµ-MYC lymphomas 
have been shown to have elevated levels of 4E-BP1 phos-
phorylation on mTOR-specific sites (Thr37/46) and the 
mTOR active site inhibitor MLN0128 was shown to induce 
apoptosis in the BL Raji cell line.90
A promising outcome of this research then, in terms of 
identifying potential strategies for the treatment of BL, is 
that mTOR activity is an attractive target for therapeutic 
 intervention. An important finding was that the combination 
of PI3K, AKT, or mTOR inhibitors act synergistically to 
induce apoptosis in combination with the BH3-mimetic com-
pound ABT-737.22 ABT-737 acts like BIM or PUMA to inhibit 
BCL-X
L
 function and induce intrinsic mitochondrial apopto-
sis (Figure 2). PI3K inhibition rendered previously resistant 
BL cells sensitive to the effects of ABT-737, indicating that 
PI3K can induce chemoresistance to agents that target one 
of the critical oncogene-induced apoptosis pathways. These 
data also imply that MCL-1 inhibitors could be effective in 
combination with BH3 mimetics or activators of wild type 
p53 as a therapeutic strategy in BL. Such combination thera-
pies may offer significant advantages over current treatment 
regimens by reducing drug-associated toxicity.
The impact of Epstein–Barr  
virus on c-MYC and PI3K
EBV persistently infects greater than 90% of the population 
and remains, in most cases, benign for life. In some individu-
als, however, EBV infection is clearly associated with the 
development of BL. It is not entirely clear how EBV infection 
may contribute to disease pathogenesis but, presumably, EBV 
infection creates the right environment for cells to undergo, 
and perhaps more significantly to survive, the process of MYC 
gene translocation. How EBV may complement the activation 
of MYC to promote pathogenesis has been reviewed com-
prehensively elsewhere.91 However, in light of new studies, 
which have now established that the PI3K/AKT/mTOR path-
way is a critical partner in MYC-driven lymphomagenesis, 
it is worth revisiting some aspects of EBV biology that may 
impact on these pathways. It is perhaps no coincidence that 
infection with this tumor-associated virus shows remarkable 
mimicry of many of the effects of the genomic mutational 
events recently described in BL.
Following infection, an initial phase of B-cell activation 
and proliferation is driven by viral genes and orchestrated 
by the viral TCF Epstein–Barr nuclear antigen (EBNA)-2.92 
Significantly, one of the main cellular genes targeted 
by EBNA-2 for this purpose is c-MYC.93,94 In addition, 
EBNA-2 and two EBV-encoded membrane proteins activate 
the PI3K pathway. EBNA-2 appears to induce phospho-
AKT via induction of the microRNA, miR-21 (probably 
through the posttranscriptional processing rather than 
by the induction of the primary transcript).95 Meanwhile, 
latent membrane protein (LMP)-2A, a mimic of functional 
BCRs, is expressed by EBV potentially to inhibit nega-
tive selection. LMP-2A constitutively activates PI3K,96,97 
thus providing the cell with the “tonic” BCR-like survival 
signals that are evident following TCF3 and ID3 mutation 
in BL. Interestingly, LMP-2A is often detected in tumor 
biopsies of EBV-related malignancies, although LMP-2A is 
down-regulated during later stages of viral latency and can, 
therefore, play no further role in promoting cell survival. It 
seems likely then, that LMP-2A may have a potential role 
in augmenting the survival of cells98 carrying tumorigenic 
genetic abnormalities within the GC, possibly by PI3K/
AKT-mediated upregulation of BCL-X
L.
96 A second EBV 
encoded membrane protein, LMP-1, functionally mimics 
activated CD40,99 requires no ligand, and is capable of trans-
forming rodent fibroblasts.100 LMP-1 signals via a number 
of intracellular pathways such as nuclear factor-kappa B,101 
mitogen-activated protein kinase,102 Janus kinase,103 but 
also, through the binding of its cytoplasmic tail to the p85 
regulatory subunit, which signals via PI3K to AKT.104,105 
Thus, through the expression of EBNA-2, LMP-1, and 
LMP-2A, EBV provides similar survival and transform-
ing signals that have been shown to cooperatively induce 
malignant transformations in BL.
There are also numerous viral products that can block 
the ability of infected cells to mount an effective intrinsic 
apoptotic response to oncogene-induced stress (reviewed 
in Spender and Inman).6 EBV blocks this response either 
by directly interfering with BAX/BAK function (mediated 
by the viral genes LMP-1, BHRF-1, and BALF-1), inducing 
expression of other prosurvival BCL-2 family members 
such as MCL-1106 and BFL-1 (induced by LMP-1),107 or by 
inhibiting the function or expression of the BH3-only pro-
teins PUMA (BHRF-1, miR-BART5) and BIM (EBNAs-3A 
and 3C).108,109 Inhibiting the function of BIM and PUMA 
or inducing MCL-1 are, as discussed previously, also the 
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consequence of promoter methylation, MYC mutation or 
increased mTORC activity, all described in BL.
In light of the evidence that EBV infection appears to 
recapitulate the events required for BL pathogenesis (ie, 
MYC induction, activation of PI3K, and inactivation of 
the intrinsic apoptosis pathway), one might expect that p53 
oncogene-induced stress response would also be targeted. 
Indeed, two potent viral transcriptional repressors (EBNA-3A 
and 3C) are implicated in the repression of p14ARF,110 which is 
required for p53 induction. There are also data reporting that 
EBV infection deubiquitinates and stabilizes the p53-negative 
regulator MDM2 (a function of EBNA-3C),111 or mediates 
p53 degradation independently of MDM2 (BZLF-1),112 thus 
reducing p53 expression. The formation of EBNA-leader 
protein (LP)/MDM2/p53 complexes has also been proposed 
to selectively block p53-mediated transcription (of p21) 
and provide an explanation as to how rapidly proliferating 
infected cells tolerate high levels of wild type p53 without 
succumbing to p53-induced cell cycle arrest.113
One deviation from the hypothesis that EBV infec-
tion exactly mimics the changes seen in BL applies to the 
expression of cyclins. Mutation and expression of cyclin 
D3 is associated with BL pathogenesis; however, cyclin D3 
expression is rarely seen in EBV-infected cells with an acti-
vated phenotype.114 The viral TCF EBNA-2 does, however, 
indirectly induce cyclin D2.94 Cyclin D2 can compensate for 
loss of cyclin D3, at least in some circumstances,115 so per-
haps cyclin D2 upregulation in the context of EBV infection 
has similar net pro-proliferative effects as cyclin D3 activity 
within BL.
Taken together, the data suggest that EBV infection may 
functionally mimic the BL cellular environment, perhaps 
enabling the genomic aberrations associated with BL to 
establish themselves during the tumorigenic process. The 
latent viral gene expression program that persists within BL 
is very restricted, involving only EBNA-1, which is required 
for viral genome maintenance, and two small RNA species 
called Epstein-Barr virus encoded small RNAs (EBER)1 and 
EBER2, whose potential targets are unknown. Both EBNA-1 
and the EBERs, however, also appear to have a role in prevent-
ing BL cell apoptosis,116 which could help promote lymphom-
agenesis. It would also be relevant to study the significance of 
infection with different EBV subtypes and their association 
with BL. EBV type 1 (also called type A) differs from type 2 
(or type B) predominantly through sequence variation of the 
EBNA-2 gene. While the type A virus is much more efficient 
than the type B virus at driving proliferation of EBV-infected 
lymphoblastoid cell lines in vitro117 (potentially via better 
induction of LMP-1 expression),118 in some areas of endemic 
BL, infection with the type 2 strain predominates.119 Differ-
ential regulation of certain cell genes does occur in response 
to type 1 and type 2 EBNA-2 expression,118 but it is presently 
unclear whether these genes may significantly affect BL 
pathogenesis. The new models of BL pathogenesis targeting 
the cell of origin may help to decipher the cooperating roles 
of mutated and viral genes in BL development – in particular, 
which EBV genes are actually required, and when they are 
required, to contribute to BL development. Such studies will 
also provide excellent model systems in which to test new 
therapeutic strategies.
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